Figures & data
Figure 1. Immunocryosurgery for the treatment of two representative patients with therapeutically challenging BCC disease: treatment course and outcomes. Panels A–D: treatment of a patient with a multitude of concurrent, almost confluent head-and-neck BCCs (Patient 1). (A) Detail of the patient's mid-face showing multiple BCCs covering most of his nose surface. Insert: illustration of the patient's head and neck region indicating the localizations of the concurrent 18 BCCs at presentation. (B) Mid-face of the patient showing multiple, almost confluent BCCs on the nose and concurrent BCCs on the cheeks. (C) The same region as in Panel B on the day of cryosurgery showing heavily inflamed tumors after treatment with daily 5% imiquimod cream for 4 weeks (during the 2 last weeks in combination with 0.1% tazarotene gel) just before the cryosurgery session. (D) The same region as in Panel B 24 months after treatment. The outcome of treatment was excellent, with minimal scarring and sustained remissions in 15/16 tumors treated by immunocryosurgery (one tumor relapsed during the 2-year follow-up: Panel D, arrow). Two BCCs – the tumor at the left lower eyelid (Panel B) and a tumor on the right lower eyelid – were surgically removed prior to the immunocryosurgery. Panels E and F: patient 2. (E) Neglected BCC relapse of the right ear 5 years after excision of the primary tumor at presentation. (F) Clinical outcome 18 months after treatment with a single cycle of immunocryosurgery.
